Latest

3 stories

Hide weekly roundups

Tuesday, September 15

Regulatory decisionatacicept Vera Therapeutics, Inc.

Vera's TRUTAKNA hits all endpoints in ORIGIN 3 final analysis for IgA nephropathy

Vera Therapeutics plans to file a supplemental BLA in Q4 2026 seeking full approval after two-year data showed stabilized kidney function and reduced disease progression.

SEC filing

Monday, August 10

Quarterly updateatacicept Vera Therapeutics, Inc.

Vera Therapeutics reports Q2 2026 results after TRUTAKNA accelerated approval

The company detailed its TRUTAKNA launch, an aligned earlier ORIGIN 3 efficacy analysis, and a planned sBLA filing, alongside a $109.5 million quarterly net loss.

SEC filing

Thursday, July 9

PeopleVera Therapeutics, Inc.

Vera Therapeutics names new Chief Regulatory Officer

William Turner steps down from the CRO role and moves to a special advisor position, with Nancy Bowman set to replace him.

SEC filing